Cannabinoids and triple-negative breast cancer treatment

Dobovišek, Luka (avtor), Borštnar, Simona (avtor), Debeljak, Nataša (avtor), Kranjc Brezar, Simona (avtor)

Triple-negative breast cancer (TNBC) accounts for about 10-20% of all breast cancer cases and is associated with an unfavorable prognosis. Until recently, treatment options for TNBC were limited to chemotherapy. A new successful systemic treatment is immunotherapy with immune checkpoint inhibitors, but new tumor-specific biomarkers are needed to improve patient outcomes. Cannabinoids show antitumor activity in most preclinical studies in TNBC models and do not appear to have adverse effects on chemotherapy. Clinical data are needed to evaluate efficacy and safety in humans. Importantly, the endocannabinoid system is linked to the immune system and immunosuppression. Therefore, cannabinoid receptors could be a potential biomarker for immune checkpoint inhibitor therapy or a novel mechanism to reverse resistance to immunotherapy. In this article, we provide an overview of the currently available information on how cannabinoids may influence standard therapy in TNBC.

• Jezik: Angleški jezik
• Ključne besede: triple-negative breast cancer, breast cancer, cancer treatment, cannabinoids, endocannabinoid system, chemotherapy, immunotherapy, immune system, tumor microenvironment, immune checkpoint inhibitors
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.02 - Pregledni znanstveni članek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2024
• Št. strani: 13 str.
• Številčenje: Vol. 15, art. 1386548
• PID: 20.500.12556/RUL-165016
• UDK: 618.1
• ISSN pri članku: 1664-3224
• DOI: 10.3389/fimmu.2024.1386548
• COBISS.SI-ID: 204044547
• Datum objave v RUL: 21.11.2024

Gradivo je del revije

• Naslov: Frontiers in immunology
• Skrajšan naslov: Front. immunol.
• Založnik: Frontiers Research Foundation
• ISSN: 1664-3224
• COBISS.SI-ID: 30774233

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: trojno negativni rak dojke, rak dojke, onkološko zdravljenje, kanabinoidi

Projekti

• Financer: ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
• Številka projekta: J3-3062
• Naslov: Avtologni imunohibridomi in napredno zdravljenje trojno negativnega raka dojk stadijev II in III

• Financer: ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
• Številka projekta: P3-0003
• Naslov: Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev